Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 15, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Reprogramming T cell fate through antibody-mediated galectin-1 blockade.

Roxana Kiyomi Mizutamari1, Juan M Pérez Sáez2, Alejandro J Cagnoni3

  • 1Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina; Centro de Excelencia en Productos y Procesos (CEPROCOR), Santa María de Punilla, Córdoba, Argentina; Departamento de Ciencias Exactas, Físicas y Naturales, Universidad Nacional de La Rioja, La Rioja, Argentina.

Methods in Cell Biology
|July 13, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Developmental Lectin-Glycan Program Enables Early Breast Cancer Dissemination and Metastatic Onset.

bioRxiv : the preprint server for biology·2026
Same author

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity.

Science advances·2026
Same author

Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies.

Biochimica et biophysica acta. General subjects·2026
Same author

ChronoRoot 2.0: an open AI-powered platform for 2D temporal plant phenotyping.

GigaScience·2026
Same author

Glycan-Binding Proteins in Immunity.

Annual review of immunology·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Galectin-1 (GAL1) promotes cancer by suppressing immunity and aiding blood vessel growth. A new assay measures GAL1

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Galectins, conserved β-galactoside-binding proteins, influence cancer progression.
  • Galectin-1 (GAL1) promotes tumor immunosuppression and angiogenesis.
  • Targeting GAL1 inhibits tumor growth and metastasis in experimental models.

Purpose of the Study:

  • To develop a functional assay for evaluating galectin-targeting agents.
  • To assess the blocking capacity of agents targeting GAL1.
  • To establish a method for determining GAL1 activity through T-cell apoptosis.

Main Methods:

  • Development of a T-cell death inhibition assay.
  • Utilizing a fully human anti-GAL1 monoclonal antibody as a model inhibitor.
  • Assessing the functional blocking activity of galectin-targeting agents.
Keywords:
Anti-galectin-1 monoclonal antibodyApoptosisCell deathGalectin-1GalectinsImmunomodulationPhosphatidylserine exposure

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Main Results:

  • The described assay provides a functional readout of GAL1 activity.
  • The assay can determine the blocking capacity of potential therapeutic agents.
  • Demonstrated utility of the assay with an anti-GAL1 antibody.

Conclusions:

  • Strategies targeting GAL1 show promise for cancer therapy.
  • A T-cell death inhibition assay is crucial for evaluating GAL1-blocking agents.
  • This assay serves as a vital tool in the development of novel cancer therapeutics.